Introduction {#S1}
============

Exosomes are small extracellular nano-sized vesicles between 30 and 150 nm in diameter ([@B39]) that were first described in the 1980s ([@B82]). They consist of one type of EVs and are categorized on the basis of their biogenesis pathways ([@B129]). Since then, exosomes have been isolated from nearly all mammalian cell types, including cells in the CNS such as neurons, astrocytes, oligodendrocytes, microglia, and Schwann cells, as well as endothelial cells ([@B49]; [@B154]). Exosomes released from the nervous system are collectively called BDEs.

To form MVBs with ILVs, early endosomes undergo inward budding ([@B31]). Then, ILVs are released into the extracellular environment as exosomes via fusion of MVBs with the plasma membrane ([@B73]; [@B123]). Alternatively, exosomal formation can be regulated by sphingolipids, ceramides and tetraspanins ([@B166]; [@B161]; [@B173]). Otherwise, MVBs can fuse with the lysosomal membrane, resulting in degradation of ILVs and recycling of their content ([@B161]; [@B94]). As a result of their origin and multifarious molecular cargo, including but not limited to gDNA, mRNA, other non-coding RNAs, lipids and proteins ([@B195]), the molecular species and relative amounts in exosomes are highly heterogeneous and complex in composition. Exosomes can randomly or selectively exhibit great variety depending on their membranes, cytosolic proteins, and nucleic acids compared with the cells that release them. Based on the proteomic and other comprehensive analyses, the heterogeneity of exosomes is conceptualized on the basis of their size, content (cargo), functional impact on recipient cells and cell of origin (source) ([@B84]). It is becoming increasingly clear that exosomes have specialized functions and play a key role in coagulation, intercellular signaling and waste management ([@B171]; [Figure 1](#F1){ref-type="fig"}).

![Biogenesis and cell-to-cell communication of extracellular vesicles (EV), especially exosomes. Exosomes are formed by the inward budding of the multivesicular body (MVB) membrane, which is formed by invagination of the endosomal membrane. Early endosomes go through transition to late endosomes and are further burdened to form late MVBs containing intraluminal vesicles (ILVs) ([@B31]). Cargo sorting into exosomes involves the endosomal sorting complex required for transport (ESCRT)-dependent mechanism, which are managed by ESCRT proteins (ESCRT-0, I, II, and III) and their accessories (ALIX, TSG101, and VPS32) ([@B77]; [@B174]), and ESCRT-independent mechanism, which are mediated by neutral sphingomyelinase 2 (nSMaseII), tetraspanins, and the chaperone heat shock proteins (HSP70 and HSC70), can develop ILVs ([@B114]). ILVs have two fates, either fusing with the lysosome resulting in the degradation of the ILVs and their contents for recycling as an endolysosomal pathway ([@B94]), or fusing with the plasma membrane where they are released into the extracellular space as exosomes through a secretory pathway ([@B73]). Microvesicles are formed directly by outward budding of the plasma membrane, a course which is managed by the ESCRT components and ADP ribosylation factor 6 (ARF6), some small GTPases, lipids, and Ca^2+^-dependent enzymatic machineries ([@B164]). Apoptotic bodies are the largest of the EVs. They "bleb" off the cell membrane and contain material from cells undergoing apoptosis, which are typically engulfed by macrophages ([@B164]). After release into the extracellular space, exosomes can be internalized by recipient cells mediated by the interaction of various exosomal surface proteins and cellular receptors via several mechanisms including phagocytosis, plasma membrane fusion, macropinocytosis and endocytosis ([@B117]). The contents of exosomes can effectively influence cellular processes through taking part in genetic/protein transfer, transcriptional regulation or post-transcriptional regulation. Alternatively, exosomes can be further fused with the lysosomes for degradation ([@B143]; [@B196]).](fnmol-13-00079-g001){#F1}

During the formation process, exosomes are comprised of enriched endosome-associated components such as flotillins and annexins ([@B175]), ALIX, the ESCRT component, tumor susceptibility gene 101 protein (TSG101) ([@B110]) and lipid rafts, including cholesterol, sphingomyelin and ceramide ([@B39]). Moreover, membrane proteins, including tetraspanins such as abundant CD9, CD63, and CD81, that are considered as markers for exosomes and play important roles in the biogenesis of endosomes or MVBs ([@B110]; [@B96]). Depending on the cell type from which they are secreted, exosome vesicles themselves also hold particular and varied types of markers that contribute to identifying their origins ([@B110]; [@B96]). For example, neuronal L1 cell adhesion molecule (L1CAM) can be used as a biomarker for isolating BDEs ([@B28]).

Once the exosomes are secreted, they can be internalized from the extracellular space by recipient cells through several mechanisms including phagocytosis, micropinocytosis, endocytosis, and plasma membrane fusion ([@B117]; [Figure 1](#F1){ref-type="fig"}). On the other hand, exosomes carrying multiple cargo with valuable biological information can also be released into most bodily fluids such as plasma, cerebrospinal fluid, urine, saliva, amniotic fluid, colostrum, breast milk, synovial fluid, semen and pleural ascites, not only in normal tissues ([@B32]; [@B117]) but also in aberrant bodies such as tumors ([@B20]; [@B141]). For the above reasons, exosomes play key roles in the management of normal physiological environments, such as immune surveillance ([@B140]), stem cell maintenance ([@B142]), tissue repair ([@B54]), and blood coagulation ([@B38]), as well as in the pathological processes associated with several diseases ([@B108]), including neurodegenerative diseases such as AD ([@B13]; [@B179]) and PD ([@B48]).

Given the characteristic described above, exosomes and their constituents represent a novel class of therapeutic targets and such features also give them advantages as biomarkers to distinguish healthy and disease states ([@B48]) and for prognosis prediction and therapy for diseases. Moreover, recent studies have demonstrated that exosomes may also be directly considered as potential therapeutic agents. For instance, mesenchymal stem cell-derived exosomes have been used in tissue regeneration ([@B100]; [@B165]) and tumor antigen-pulsed dendritic cell-derived exosomes have been developed for cancer immune response modulation ([@B206]). Remarkably, exosomes have an efficient capability to cross the BBB ([@B21]). In particular, exosomes isolated from CSF are rich in proteins that originate from the brain such as neuron-specific markers, microglial markers (CD11b and CD45) and Apo-E ([@B25]), making them potential novel drug delivery vehicles for treating nervous system diseases. Here, we mainly discuss and summarize the role of BDEs in normal biological processes in the CNS as well as the aberrant pathological state of AD and focus on explaining how exosomes can be targeted or directly exploited as biomarkers or therapeutics in AD.

Physiological Roles of BDEs in the CNS {#S2}
======================================

Exosomes exert their effects on essential biological processes throughout the body including the CNS by different mechanisms. These mechanisms include cell surface receptors activation through direct binding to lipid ligands and proteins, exosomal membrane fusion contents with the recipient cell plasma membrane and effectors delivery. Some of these effectors are oncogenes, transcription factors, small and large non-coding regulatory RNAs (such as miRNAs) and mRNAs, as well as infectious particles such as amyloid-β (Aβ)−derived ([@B13]) and α-synuclein ([@B48]) into recipient cells ([@B20]; [@B105]; [Figure 1](#F1){ref-type="fig"}). In this manner, exosomes participate in the maintenance of normal physiology ([Figure 2](#F2){ref-type="fig"}).

![Intercellular communication of BDEs in the CNS in (patho) physiological course in AD. Exosomes secreted from oligodendrocytes, microglia, astrocytes and mesenchymal stem cells includes host cell derived cytosolic proteins, cytokines and transcription factors, Aβ scavenger enzymes, Aβ ([@B143]; [@B196]) and tau protein ([@B39]) along with nucleic acids (DNA, mRNA, miRNA and/or lncRNA and/or cirRNA) ([@B20]; [@B105]; [@B195]). They afford positive as well as negative effect on the neurons depending on the cargo they carry. In the physiological condition, exosomes benefit to the reciprocal communication between neural cells (e.g., neuron-glia interaction), synaptic plasticity, neuronal development and neuroimmune communication. In the early stage of AD, the microglia activation by Aβ has neuroprotective effect because it induces phagocytosis and Aβ clearance ([@B15]; [@B75]). The microglia stimulation by astrocyte released ATP induces the secretion of exosomes including P2X7 receptor as a defensive strategy to escape astrocyte signaling ([@B15]; [@B75]). In the latter stage of AD, microglia secrete exosomes containing pro-IL1β, active caspase-1 and soluble toxic Aβ that have detrimental effects on neurons ([@B14]; [@B168]). Neurodegenerative associated proteins such as Aβ, Tau, prions ([@B49]) and α-synuclein ([@B48]) can also be derived from neural derived exosomes, leading to the spread of protein aggregate seeds and disease progression. In addition, these exosomes could be exported via blood-brain barrier as circulatory EVs, which can be used for disease-specific biomarkers, even future for therapeutic researches ([@B164]).](fnmol-13-00079-g002){#F2}

Particularly, in the CNS, exosomes can be released from virtually all cell types, including various types of neurons, astrocytes, oligodendrocytes, microglia, and Schwann cells, as well as endothelial cells ([@B49]; [@B154]). EVs carry and release multiple molecules related to neuronal function and neurotransmission in the brain, which is beneficial for the reciprocal communication between neural cells (e.g., neuron−glia interactions), synaptic plasticity, neuronal development, and neuroimmune communication ([@B52]; [@B139]; [@B78]; [Table 1](#T1){ref-type="table"}).

###### 

Exosome is a double-edged sword in nervous system.

  **Condition**              **Function**                                                             **References**                
  -------------------------- ------------------------------------------------------------------------ ----------------------------- ------------------
  Physiological roles        Neuron−glia communication                                                Neuron and microglia          [@B53]
                                                                                                      Neuron and astrocytes         [@B118]; [@B130]
                                                                                                      Neuron and oligodendrocytes   [@B97]
  Pathological roles in AD   Synaptic plasticity and neurotransmission                                [@B26]; [@B95]                
                             Enhancement of neuron protection                                         [@B66]                        
                             Improvement neuronal development                                         [@B44]                        
                             Carry the two hallmarks of AD brains, Aβ, and hyperphosphorylated tau    [@B148]                       
                             The spread of oligomers and neurotoxicity                                [@B69]                        
                             Carry the synaptic proteins                                              [@B62]                        
                             Carry the ceramide and sphingosine-1-phosphate (S1P)                     [@B199]; [@B42]               
                             Containing tyrosine phosphorylated insulin receptor substrate 1 (IRS1)   [@B86]                        

Neuron-Glia Communication via Exosome Secretion {#S2.SS1}
-----------------------------------------------

Neurons and glial cells (a class of cells that mainly includes microglia, astrocytes, and oligodendrocytes) orchestrate CNS homeostasis via numerous mechanisms of intercellular communication. Exosomes might regulate the physiological condition of the recipient cells and interactions between various neural cells. For example, upon activation of glutamatergic synapses, cortical neuron-derived exosomes are selectively delivered to neurons but not glial cells ([@B95]). Recent studies using CD63-GFP positive intraluminal vesicles as exosomal reporter in mice have demonstrated that exosomes participate in mediating neuron to astroglia communication in the CNS ([@B118]). Furthermore, miRNAs (especially miR-124a) in exosomes isolated from neuron-conditioned medium possess excitatory amino acid transporter 2, a necessary mediator of glutamate uptake via the internalization of exosomes into astrocytes ([@B121]). However, exosomes also participate in reciprocal oligodendrocyte-neuron communication and transfer cargo from oligodendrocytes to neurons ([@B52]). Although exosome-mediated communication and the manner by which exosomes select their recipient cells are largely unclear, emerging evidence suggests that exosomes serve as selectively important conveyers for neuron-neuron or neuron-glia interaction in the brain by transmitting genetic information, various bioactive proteins, and lipids.

Synaptic Plasticity and Neurotransmission by the Release of Exosomes {#S2.SS2}
--------------------------------------------------------------------

Maintenance and improvement of synaptic connectivity in the adult brain are crucial for cognitive function. Neural synaptic plasticity is mediated not only by neuron-specific progression but also by glial cells, such as astrocytes and microglia ([@B122]). Under resting conditions, synaptic vesicles are reposited in the cytoplasm of the nerve terminal. Many synaptic vesicles stick on some specialized sites at the presynaptic plasma membrane named active zones. During incoming action potentials, exocytosis of synaptic vesicles confirm how much transmitter is released from nerve terminals ([@B79]). In addition to typical synaptic neurotransmission, signal transduction of neurons via the secretion of exosomes can induce a range of neurobiological functions including synaptic plasticity ([@B26]; [@B95]). During management of synaptic plasticity, PC12 cell-derived exosomes can stimulate synaptic pruning through enhancement of the complement component 3 level in microglial MG6 cells ([@B11]). For instance, enhanced secretion of cortical neuron-derived exosomes containing neurotransmitter receptors leads to increased glutamatergic activity ([@B99]). Additionally, by managing the number of AMPA receptors for glutamate transmission, neuronal-derived exosomes might affect synaptic plasticity ([@B99]).

Enhancement of Neuron Protection and Neuronal Development Through Exosomes {#S2.SS3}
--------------------------------------------------------------------------

Although the understanding of astrocyte-neuron communication via exosomes remains unclear, evidence supports that it does occur, and this communication manner is required for neuronal cell survival ([Figure 2](#F2){ref-type="fig"}; [@B130]; [@B111]). Neuroprotective signaling is essential for neuronal growth and survival. PrP is a physiologically important receptor protein that protects against oxidative stress in the CNS. Protection of neurons through astrocyte-derived exosomes is dependent on astrocyte-derived exosomal PrP transport into neurons ([@B66]). In addition, studies have demonstrated that microglia and oligodendrocyte-derived exosomes contribute to neuronal energy metabolism by transferring several enzymes involved in energy metabolism ([@B97]; [@B44]). Thus, exosomes mediate several vital processes involved in normal brain function. Taken together, these findings suggest that exosome-mediated cell communication is emerging as a method of mediating neuron protection.

Pathological Roles of BDEs in AD {#S3}
================================

Increased secretion of exosomes is generally thought to occur in response to stress or pathological conditions ([@B169]; [@B151]; [@B56]), such as hypoxia ([@B93]; [@B126]), alcoholism ([@B120]), cisplatin- ([@B189]), or irradiation-induced DNA damage ([@B106]), and oxidative stress ([@B10]). Neuron-derived exosomes including particular proteins associated with neurodegenerative diseases can be secreted from the affected neurons ([@B179]). In the case of AD, there are two hallmarks of AD brains, Aβ and hyperphosphorylated tau, interact with specific endosomes and may contribute to exosome biogenesis in AD ([@B148]). Additionally, exosomal proteins, such as flotillin-1 and Alix, were observed to accumulate around amyloid plaques in AD patients ([@B140]). The formation, secretion or uptake of exosomes plays a dual role in the spread of oligomers and neurotoxicity ([Table 1](#T1){ref-type="table"}).

Exosomes Containing Aβ in AD {#S3.SS1}
----------------------------

Amyloid β-protein is a C-terminal cleavage product of the transmembrane APP produced by β- and γ-secretase ([@B40]; [@B119]). AD is characterized by the presence of aggregates of pathologically misfolded proteins in the brain, including extracellular senile plaques mainly consisting of Aβ ([@B16]). Numerous reports have described these proteins and their substrates within exosomes of *in vitro* AD models and in exosomes derived from neurons of AD patients ([@B42]; [@B201]).

Although most AD cases are sporadic, there is a minority patients from mutations in the genes encoding APP or during sequential cleavages by β- and γ-secretase enzyme activities ([@B27]). *In vitro*, exosomes isolated from neuronal cell lines show that inducing AD mutations can increase sAPP protein β, sAPPα ([@B188]; [@B157]) and soluble Aβ1-42 ([@B46]). N2a cells expressing human APP with the autosomal dominant Swedish mutation contain Aβ peptides as well as the C-terminal fragments of APP have also shown increase of production of C-end terminal fragments (a byproduct of APP after β-secretase processing) ([@B102]), β-secretase in released exosomes, and co-localization of β-secretase enzyme 1 with early exosome markers ([@B188]). Vesicles released by Aβ-treated astrocytes contain the pro-apoptotic prostate apoptosis response 4 (PAR-4) protein and these vesicles cause PAR-4 associated apoptosis in naive cultures ([@B177]). Experiments involving the medium of neural cells expressing familial AD presenilin 1 mutations show that Aβ is associated with exosomes during their excretion process ([@B47]).

*In vivo*, rodent exosomes can contain Aβ, BACE1, and presenilin 1 and 2 ([@B155]). Exosomes isolated from bodily fluids of AD mouse model, including blood, CSF and urine, display indicative increase in the C-terminal fragments of APP ([@B102]; [@B119]). Exosomes isolated from bodily fluids of AD patients exhibit a remarkable increase soluble Aβ1--42 in [@B2]; [@B186], [@B68], [@B69]. Amyloid plaques in AD brains also contain an exosome marker ([@B2]; [@B186]; [@B68], [@B69]). The muskelin protein is involved in reorganization of the cytoskeleton and has been shown to be involved in the determination of either lysosomal degradation or exosome secretion of PrP ([@B74]). Importantly, PrP is a receptor for Aβ and is reported to increase the pathogenicity of AD ([@B30]). Muskelin may play a critical role in this type of amyloidosis.

The above data suggested the hypothesis that exosomes could seed Aβ aggregation ([@B43]). However, neuronal exosomes can also restrain Aβ oligomerization and accelerate Aβ fibril formation, facilitating microglia-mediated Aβ clearance *in vitro* ([@B199]). Moreover, in an AD mouse model, intracerebral loading of glycosphingolipid-enriched exosomes led to trapping and transporting Aβ into microglia, leading to a decrease in Aβ pathology ([@B200]). These results might explain why, at least under some circumstances, exosomes associated with Aβ have a physiological, neuroprotective function ([@B198]). It is also possible that in the brain as exosomes are secreted by various cell types (e.g., neurons, microglia, and astrocytes), they might exhibit contrary effects or the exosomal membranes might promote Aβ aggregation independent of protein-associated exosomal functions (e.g., Aβ degradation by exosomal insulin-degrading neprilysin or enzymes) (reviewed in [@B43]).

Exosomes Containing Hyperphosphorylated Tau in AD {#S3.SS2}
-------------------------------------------------

The gradual deposition of hyperphosphorylated tau protein within specific neurons is pivotal to the tauopathy of AD ([@B145]; [@B163]). Under normal physiological conditions, incorporation of neuronal microtubule-associated protein tau for microtubule elongation is a crucial event of neuronal synapse formation and synaptic plasticity. Additionally, intracellular tau also participates in neurite outgrowth, axonal transport, chromosome stability, regulation the cellular transcriptome and the structural architecture of heterochromatin (for more details see the review by [@B160]). Extracellular tau is also secreted into brain interstitial fluid ([@B193]) and may contribute to some characteristics of sleep ([@B112]). The above functions rely on the site-specific phosphorylation of tau ([@B85]) in normal condition. However, hyperphosphorylation and aggregation of the microtubule-associated tau protein into intracellular neurofibrillary tangles is one of the classical pathological hallmarks of advanced-stage AD ([@B80]; [@B115]).

During the progressive accumulation of neurofibrillary tangles, tau becomes hyperphosphorylated in neurons. Meanwhile, the cellular clearance machinery takes up tau for degradation and packaging in exosomes ([@B144]; [@B24]; [@B133]). In an adeno-associated virus-based mouse model revealing rapid tau propagation, microglia help to spread tau through exosome release, and depletion of microglia or inhibition of exosome synthesis significantly decreases the propagation of tau *in vitro* and *in vivo* ([@B9]). In another mouse model of tauopathy, aggregated tau was isolated from and transmitted through brain exosomes ([@B9]). In these mice, exosomes that were isolated from the brains of tau transgenic rTg4510 mice containing human four-repeat tau with the P301L mutation accelerated pathological tau phosphorylation and oligomer formation ([@B135]), indicating that neuronal exosomes containing human mutated tau are toxic to the recipient neurons *in vivo* ([@B12]). Recently, *BIN1* was found to support spreading of tau via exosome release in mice. Tau-containing exosomes isolated from the CSF of AD-affected individuals who contain *BIN1*-associated genetic variants in AD etiology showed seeding competence ([@B33]). In human patients, compared with BDEs obtained from the plasma or serum of age-matched controls, BDEs from AD patients showed a 3-20-fold increase in tau phosphorylation at threonine 181 (p-T181-tau) and serine 396 (p-S396-tau) ([@B33]). Moreover, compared with AD patients who had only been diagnosed with mild cognitive impairment, p-T181-tau levels were significantly higher in BDEs isolated from the plasma of later-stage AD patients ([@B186]), demonstrating either a dysfunction of the clearance ability or an increase in pathogenicity of exosomes in later disease states of AD. p-T181- and p-S396-tau were significantly decreased in BDEs of patients 1--10 years prior to their AD diagnosis ([@B51]).

Exosomes Containing Synaptic Proteins in AD {#S3.SS3}
-------------------------------------------

One consequence of AD is neuron loss and dysfunction. The levels of synaptic proteins, including synaptophysin, synaptotagmins, synaptobrevin, synaptopodin, Rab3A, GAP 43, and neurogranin, were decreased in the BDE cargo from the plasma of AD patients ([@B63]). Additionally, low-density LRP 6, REST, heat shock factor protein 1, HSP, and AMPA receptor levels are also lower in BDEs from the plasma of AD patients ([@B61], [@B63]; [@B186]). Furthermore, neurexin 2α, GluA4-containing glutamate receptor, and neuroligin 1, essential proteins for long-term potentiation processes, were all significantly reduced in BDEs from the plasma of patients 6−11 years prior to AD diagnosis and, along with neuronal pentraxin 2, were all downregulated in BDEs ([@B60], [@B64]). These proteins are all involved in normal homeostasis of neurons. Further research into these proteins in BDEs could be beneficial for the search for earlier biomarkers of AD.

Ceramide and Sphingosine-1-Phosphate (S1P) in Exosomes in AD {#S3.SS4}
------------------------------------------------------------

Activated sphingolipids are signaling molecules that serve as intracellular second messengers and include ceramide, sphingosine, and their derivatives, 1-phosphates (C1P and S1P, respectively) ([@B35]). Exosomes are sphingomyelin- and ceramide-enriched vesicles formed inside MVEs and then are secreted when the MVE membrane fuses with the plasmalemma. Exosomes can serve as a vehicle for the extracellular secretion and cell-to-cell transport of Aβ, α-synuclein and tau protein, possibly further facilitating the spread of toxic protein aggregation ([@B125]; [@B178]). S1P receptor (S1PR) signaling has been reported to participate in exosomal cargo sorting. Activity of the S1PR-mediated Rho family of GTPases is essential for this process and Gβγ inhibitors inhibit this activity ([@B83]). The secretion of exosomes can be regulated by the activation of neutral sphingomyelin synthase 2 (SMS2) and sphingomyelinase 2 (nSMase2), demonstrating distinct functions for these enzymes in AD ([@B199]; [@B42]). Additionally, ceramide/sphingolipid shortage results in enhanced secretion of sAβPPα, the product of non-amyloidogenic cleavage. However, this shortage gives rise to increased secretion of Aβ42 at the same time, probably via regulation of raft-associated proteins, resulting in alteration of the α- *vs.*β-cleavage ratio ([@B199]; [@B42]). Enhanced endogenous ceramide and exogenous additional ceramide both elevate the Aβ level ([@B137]; [@B150]). The above research suggests the significance of the ceramide/sphingolipid levels in the process of AD.

Exosomes Containing Other AD-Associated Proteins {#S3.SS5}
------------------------------------------------

Dysregulation of insulin by the CNS and peripheral hyperinsulinemia have been reported as other events highly associated with AD ([@B36]; [@B37]; [@B91]). A low tyrosine phosphorylated insulin receptor substrate 1 (IRS1) to serine phosphorylated IRS1 ratio is a characteristic of insulin dysregulation ([@B3]; [@B45]) and is related to greater brain atrophy in AD patients ([@B124]). BDEs isolated from the plasma of human AD patients have revealed an enhancement in serine phosphorylation in IRS1 ([@B86]). This study demonstrated that significant differences in the IRS1 levels were recognizable up to 10 years prior to clinical onset of AD, which suggests that proteins within BDEs that are involved in insulin disruption may potentially be useful biomarkers for clinical diagnosis.

Moreover, exosomes have the ability to spread toxic proteins through PrP activity ([@B71]). PrP is a cell surface-anchored protein that is highly related to AD pathology ([@B89]). Its pathological, misfolded form is associated with spongiform encephalopathy ([@B136]; [@B159]). Studies in animal models of AD have demonstrated that the PrP receptor is essential for the cognitive impairment linked to Aβ ([@B57]). Additionally, growing evidence indicates that prion receptor on exosomes are capable of transmitting pathological substances ([@B50]; [@B71]). Aberrant autophagy is likely to play a role in this process ([@B1]). However, further research is needed to explore the potential mechanism connecting exosomes, AD pathogenesis, and autophagy.

Exosomal MiRNA as a Diagnostic Biomarker for AD {#S4}
===============================================

Generally, the biomarkers used for AD diagnosis include the expression of Aβ and pTau ([@B1]), and methods such as neuropsychological testing and specialized brain imaging techniques have also been widely used for diagnosis of AD. Unfortunately, most AD patients are asymptomatic during the pre-clinical stages, which may last up to 17 years or longer ([@B176]). Therefore, it is important to exploit early diagnostics to confirm and treat individuals who are at risk before severe and irreversible neuronal pathology occurs.

MiRNAs are a family of 18--22 nt single-stranded RNAs that post-translationally communicate with and regulate the expression of mature mRNAs. Single upregulated miRNAs can target various mRNAs to decrease their expression and multiple miRNAs can target a single mRNA ([@B153]; [@B149]). Studies have demonstrated that mRNA and miRNA species are present in exosomes. It is possible that some mRNA sequences are definitely targeted for secretion by these vesicles ([@B170]; [@B172]). Exosomal miRNAs play essential roles in intercellular communication between cell membranes in the CNS and in disease progression. Exosomal miRNAs are also ideal targets for use as potential biomarkers in clinical diagnostics or therapies as they can be analyzed through neuronal exosomes in the patient's body fluids (A). Indeed, some research has illustrated that proteins and miRNAs can be transferred from glia to axons ([@B158]). It is assumed that miRNA signaling can impact neurodegenerative diseases via the dysregulation of tau, leading to neurotoxicity. One study convincingly demonstrated that, in brain tissues obtained at autopsy from AD patients and from those with severe primary age-related tau pathology, the level of the highly conserved miRNA-219 was decreased in the brain ([@B147]). Several reports have illustrated that high expression of tissue-specific miRNAs in the brain, such as miR-9, miR-29a/b, miR-107, miR-124, miR-128, miR-134, and miR-137, may result in defective neuronal development ([@B152]; [@B88]; [@B76]). In addition, other miRNAs are also abnormal in brain tissues during neurodegenerative processes. These specific miRNAs, including miR-132 and miR-212, are among the most robustly declining miRNAs in neurodegenerative diseases, including AD ([@B29]; [@B72]; [@B187]; [@B101]), Huntington's disease ([@B81]; [@B128]), PD ([@B19]), schizophrenia and bipolar disorders ([@B134]; [@B90]) and frontotemporal dementia ([@B23]; [@B72]).

Remarkably, miRNAs that were found to be greatly expressed in the brain were also detected in human body fluids such as the plasma, urine, and CSF. The levels of brain-enriched miRNAs including miR-9, miR-29a, miR-29b, and miR-137 have been found to be significantly decreased in plasma samples collected from AD patients ([@B55]). Both miR-128 and miR-134 were also examined in patients with mild cognitive impairment, which is an early stage of AD ([@B156]). These miRNA biomarkers in the blood represents a clinical advantage for early disease diagnosis, but differential miRNA expression may not accurately rescue abnormal miRNA expression in the brain. The CSF represents a more relevant and suitable source for the diagnosis of CNS disorders such as AD ([@B4]; [@B131]; [@B172]) because CSF is a clear biological fluid produced in the choroid plexus of the brain that circulates via the inner ventricular system, crosses the BBB, and is absorbed into the bloodstream. The levels of target candidate miRNAs such as miR-9, miR-146a, and miR-155 were shown to be greatly increased in CSF from AD patients compared with those in age-matched controls, as quantified by microarrays and qRT-PCR ([@B4]; [@B113]). Currently, urine is collected and analyzed for biomarker discovery and diagnostic purposes in clinical practice ([@B183]; [@B17]). Exosomes can be purified from the urine using various methods such as differential ultracentrifugation ([@B6]), which is highly valuable for investigating whether miRNAs can be detected in the urine. However, it remains difficult to determine whether the alteration in miRNA levels in humans is a cause or consequence of the neurodegenerative process. Investigation of miRNA analysis profiles in AD animal models might help to solve this problem. Additionally, the potential to test miRNAs in biological body fluids may contribute to developing and promoting the discovery of specific biomarkers for neurodegenerative diseases such as AD.

Development of a Brain-Derived Exosomal Biomarker for AD {#S5}
========================================================

Currently, a mixed population of exosomes from various types of cells can be separated from biological fluids by multiple techniques such as classically differential ultracentrifugation, immunomagnetic beads and size exclusion chromatography ([@B107]; [@B197]). Moreover, exosomes have a lipid bilayer to protect their cargo, which is used downstream, from RNAse treatment to be confirmed whether the miRNAs/mRNA analyzed are inside the exosomes or not ([@B22]). This mixed population of exosomes may be recognized by western blots or mass spectrometry using proteins that are involved in the formation process of ILVs ([@B110]) as mentioned and discussed at the beginning of this manuscript. It is worth noting that many of these markers are not exclusive to exosomes and it is necessary to further examine the characteristics of exosomes ([@B180]). In the CNS, investigating cells from the brain may afford insights into the mechanisms of brain diseases ([@B143]). Isolating neuronal exosomes from cells related to AD may bridge the gaps in knowledge of peripheral biomarkers and provide mechanistic insight to this disease. Recently, a precipitation/immunoaffinity system has been developed to isolate neuron-derived and astrocyte-derived exosomes from the blood of AD patients ([@B60]). Data from these studies suggest that BDEs from blood plasma and measurement of certain forms of tau in BDEs can be used as diagnostic and prognostic biomarkers for AD ([@B67]; [@B143]).

Enrichment of a specific neuron-derived population of exosomes permits monitoring of target cells of interest ([Table 2](#T2){ref-type="table"}). Collectively, although exosome transfer of Aβ seems to mainly occur in AD and can be exploited as a helpful biomarker of the disease course, development of additional exosome biomarkers could contribute to a more accurate diagnosis of AD and discovering further close connections between the marker and mechanisms of the early stage of AD as well as other neurodegenerative diseases.

###### 

The biomarker of different neural derived exosomes (NDEs).

  **Exosomes isolated from different cell types**                                       **Biomarker**                                         **Function**
  ------------------------------------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cortical neurons-derived exosomes; immature and mature hippocampal neurons exosomes   The GluR2/3 subunits of glutamate receptors           Neuronal markers and play key roles in virtually all excitatory neurotransmission in the brain [@B49].
                                                                                        L1 cell adhesion molecule (L1CAM)                     Neuronal markers, cell adhesion molecule with an important role in the development of the nervous system [@B99].
  Microglia-derived exosomes                                                            Ionized calcium binding adaptor molecule 1 (Iba1)     A microglia/macrophage-specific calcium-binding protein with actin-bundling activity that participates in membrane ruffling and phagocytosis in activated microglia [@B138].
  Astrocytic-derived exosomes                                                           Glutamine aspartate transporter (GLAST)               Selective markers of astrocytic plasma membranes [@B138].
                                                                                        Glial fibrillary acidic protein (GFAP)                A specific marker for astrocytes; the astrocytic cytoskeleton [@B63].
                                                                                        Glutamine synthetase (GS)                             Astrocyte marker, it catalyzes the production of glutamine and 4-aminobutanoate [@B63].
  Oligodendrocytes-derived exosomes                                                     Myelin proteolipid protein (PLP)                      Oligodendrocytes marker, it is the major myelin protein from the central nervous system. It plays an important role in the formation or maintenance of the multilamellar structure of myelin [@B97].
                                                                                        2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP)   Oligodendrocytes marker, it belongs to the cyclic nucleotide phosphodiesterase family [@B97].

Exosomes as Novel AD Therapeutics {#S6}
=================================

The BBB is a continuous endothelial membrane within brain microvessels and is sheathed by mural vascular cells and perivascular astrocyte end-feet, which seal the cell−to−cell contacts to prevent the transmission of potentially toxic compounds between the brain and the blood ([@B116]). In addition to transmembrane diffusion of small (\<400 Da) lipid-soluble molecules, the BBB permits selective transport of some compounds into and out of the brain ([@B146]).

Exosomes have an inherent ability to cross the BBB, and because their properties remain active in the brain, they are ideal drug delivery vehicles. This BBB-penetrating capacity, which was first reported by [@B7], resulted in effective delivery of small-molecule drugs to the brain through systemic injection of naked exosomes in mice, leading to promotion of drug-mediated biological responses ([@B205]). Later studies have been successful in transmitting exosomes through intranasal injection into the mouse brain ([@B5]). Recently, a study using rats identified that the fluorescently tagged forebrain astrocyte protein aldolase C was selectively expressed in brain tissue and could be recovered in exosomes in the blood ([@B142]; [@B65]). This study affords evidence of communication mediated by exosomes from the brain to the rest of the body ([@B142]; [@B65]). Evidence from these studies illustrates that exosomes can cross the BBB in a bi-directional manner; however, their method of accurately crossing the BBB remains unclear and requires further study.

In contrast, while exosomes may play a role in the spreading of AD, some studies have shown a positive effect of introducing non-pathogenic exosomes to change disease duration and progression ([Table 3](#T3){ref-type="table"}). In animal studies, this therapeutic effect was found when exosomes from young mice were observed to significantly downregulate aging-associated signaling molecules such as IGF1R and upregulate telomerase-related genes such as *Men1, Mre11a, Tep1, Terf2, Tert*, and *Tnks* in aged mice ([@B103]). Furthermore, exosomes injected into the brain of transgenic mouse models of AD can help to decrease toxic oligomers and fibrils in a microglial-dependent manner following intracerebral administration, contributing to the clearance of Aβ *in vivo* ([@B199], [@B200]; [@B198]). Other researchers have suggested that mesenchymal stromal-derived exosomes may have a therapeutic effect *in vivo* on the advancement of neurovascular plasticity in other neurodegenerative diseases such as stroke ([@B191]).

###### 

Exosome administration for the treatment of AD and other neurological disorders.

  **Disease**           **Animal model**                              **Source**             **Administration**                       **Proposed mechanism and results**   **References**                                                                                                                                                                                                                            
  --------------------- --------------------------------------------- ---------------------- ---------------------------------------- ------------------------------------ ------------------------------------------------ ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
                                                                                             Concentration (Total amount)             Route                                Period (time)                                    Sampling/Sacrifice                                                                                                                                                                       
                        APP^sweInd^                                   N2a cells              2 mg / mL, 0.25 μL/h (168 μg)            Dentate gyrus                        14 days (continuously)                           14 days after surgery              Aβ clearence. Aβ level ↓; Amyloid deposit ↓; Synaptotoxicity ↓                                                                                        [@B200], [@B201]
                        APP^sweInd^                                   Plateletfreeplasma     3 μg / 3 μL (3 μg)                       Dentate gyrus                        Single injection                                 3 days / 20 days after injection   Co-localization (exosome and Aβ)                                                                                                                      [@B203]
                        hiPSCs Injected mice                          Tau mutation hiPSCs    0.5 μg / 2 μL (0.5 μg)                   Hippocampus                          Single injection                                 1 m / 2 m after injection          Tau propagation. Neurodegeneration ↑                                                                                                                  [@B185]
                        5XFAD pups                                    Astrocyte              NA                                       Brain                                Single injection                                 48 h after injection               Aβ plaque ↓ by exosome ↓. nSMase2 ↓; exosome ↓; Aβ plaque ↓                                                                                           [@B42]
                        Aβ-derived diffusible ligands injected mice   N2a cells human CSF    4 μg / 5 μL 4 μg                         I.C.V.                               Single injection                                 NA                                 Synaptic plasticity. LTP↑, Aβ action ↓                                                                                                                [@B8]
                        AD mice                                       hUmbilical cord MSCs   30 μg / 0.1 mL 120 μg                    I.V.                                 2 month (biweekly injection)                     1 m after injection                Neuron inflammation↓. Aβ deposit ↓; activation of microglia ↓; pro-inflammatory levels ↑; anti-inflamatory cytokines ↓                                [@B41]
                        APP^sweInd^                                   (hypoxia) PC-MSCs      150 μg / 80 μL 1200 μg                   I.V.                                 4 month (biweekly injection)                     5 h after injection                Neuroprotection and Immunomodulation. Plaque deposition ↓; Aβ level ↓; activation of astrocytes ↓; activation of microglia ↓; TNF-α, IL-1β↓; IL-4 ↑   [@B34]
  Stroke                MCAo, rat                                     MSCs                   3 × 10^6^ / mL 3 × 10^6^                 I.V.                                 24 h after surgery (single injection)            14 days after surgery              White matter repair                                                                                                                                   [@B34]
                        MCAo, rat                                     MSCs                   100 μg / 0.5 ml 100 μg                   I.V.                                 24 h after surgery (single injection)            28 days after surgery              White matter repair                                                                                                                                   [@B191]
                        MCAo, rat                                     MSCs                   100 μg/0.5 mL 100 μ[g]{.ul}              I.V.                                 24 h after surgery (single injection)            28 days after surgery              White matter repair                                                                                                                                   [@B190]
                        Embolism, mouse                               NSC EV                 NA                                       I.V.                                 2 / 14 / 38 h after surgery (triple injection)   96 h after surgery                 Immune modulation                                                                                                                                     [@B182]
                        MCAo, pig                                     NSC EV                 NA                                       I.V.                                 2 / 14 / 24 h after surgery (triple injection)   1 / 84 days after surgery          Reduction in edema                                                                                                                                    [@B181]
                        ICH, rat                                      MSCs                   NA                                       I.V.                                 12 h after surgery (single injection)            2 / 7 / 28 days after injection    Immunosuppression                                                                                                                                     [@B127]
                        Rat                                           MSCs                   NA                                       NA                                   NA                                               NA                                 White matter remodeling                                                                                                                               [@B18]
  TBI                   CCI, rat                                      hMSCs                  100 μg / 0.5 ml 100 μg                   I.V.                                 12 h after surgery (single injection)            35 days after surgery              Angiogenesis and neurogenesis                                                                                                                         [@B202]
                        ICH, rat                                      MSCs                   3 × 10^6^ MSCs 3 × 10^6^                 I.V.                                 12 h after surgery (single injection)            12 days after surgery              Angiogenesis and neurogenesis                                                                                                                         [@B92]
                        TBI, swine                                    MSCs                   1 × 10^15^; 1 × 10^13^                   I.V.                                 6 h / 1 / 5 / 9 / 13 days                        30 days after surgery              Neuroprotection                                                                                                                                       [@B184]
  Fetal hypoxia         OCD singleton fetuses                         MSCs                   2.0 × 10^7^ cell; 4.0 × 10^7^            I.V.                                 1 h / 4 days (2)                                 7 days after surgery               Neuroprotection                                                                                                                                       [@B184]
  ICH                   ICH, rat                                      MSCs                   100 μg protein I.V., 200 μg              I.V.                                 24 h after surgery (single injection)            28 days after surgery              Neurovascular and white matter remodeling.                                                                                                            [@B70]
                        ICH, rat                                      MSCs                   100 μg protein I.V., 100 μg              I.V.                                 24 h after surgery (single injection)            28 days after surgery              White matter repair                                                                                                                                   [@B127]
  Focal ischemia        Photo thrombosis, mouse                       BM-MSCs                NA                                       I.V.                                 24 h after surgery (single injection)            2 h after injection                Neurogenesis                                                                                                                                          [@B194]
  ASD                   BTBR T+tf/J mouse                             hMSCs                  3.81 × 10^8^ particles/5 μL 1.9 ×10^9^   I.N.                                 12 days (every other day injection)              Behavior test                      Social interaction                                                                                                                                    [@B132]
  Inflammation          C57BL/6j mice                                 EL-4 T cell            2 μg / 2 μL 10 μg / 10 μL                I.N.                                 10 min (every 2 min injection)                   After administration               Anti-inflammation                                                                                                                                     [@B205]
  Status epileoticus    C57BL/6J mice                                 MSCs                   ∼ 5 μg 30 μg / 150 μL                    I.N.                                 18 h (every 5 min)                               4 days after administration        Neurogenesis and memory dysfunction                                                                                                                   [@B109]
  Bacterial infection   C57BL/6J mice                                 BMDCs                  25 μg / 30 μL 75 μg / 90 μL              I.N.                                 2 week (three doses)                             2 week after immunization          Macrophage and dendritic cell activation                                                                                                              [@B58]
                        C57BL/6J mice                                 Bone marrow cells      25 μg / 30 μL 75 μg / 90 μL              I.N.                                 2 week (three doses)                             2 week after dose                  Potential mechanism for antigen cross-priming                                                                                                         [@B59]

APP

swelnd

, mice expressing the human APP bearing the Swedish and Indiana (KM670/671NL, V717F) mutations (J20); ASD, autism spectrum disorders; BM-MSCs, bone marrow mesenchymal stem cells; CCI, controlled cortical impact; CSF, cerebrospinal fluid; hiPSCs, human induced pluripotent stem cells; EV, extracellular vesicles; ICH, intracerebral hemorrhage; I.C.V., intracerebroventricularly infusion; IL, interleukin; I.N., intranasal administration; I.V., intravenous injection; LTP, Long-term potentiation; MCAo, middle cerebral artery occlusion; MSCs, mesenchymal stem cells; NA, not applicable; NSC, Neural stem cell; OCD, occluder; PC-MSCs, preconditioned mesenchymal stem cells; TBI, traumatic brain injury; TNF-α.

Additionally, directed exosomal transmission systems for precision nanomedicine have attracted extensive interest across the fields of pharmaceutical sciences, molecular cell biology and nanoengineering ([@B204]). Exosomes are also a promising type of novel drug delivery vehicle because of their ability to cross the BBB and shield their cargo from enzymatic and chemical degradation. Recent developments regarding nanoengineering using targeted exosomes for therapeutic purposes have been conducted by researchers, for example, [@B192], [@B167].

Introducing exogenous exosomes into the CNS because they can effectively cross the BBB is a potentially novel strategy for AD therapies ([@B21]), and their innate secretion of enzymes could be beneficial for degrading toxic fibrils ([@B87]). The field of EV research is still at the initial stage in the CNS and yet improved therapeutic applications are already being developed.

Opportunities and Challenges {#S7}
============================

Quantifying changes in EV cargo would be extremely difficult because of the lack of unique region-specific markers for circulating exosomes and the inaccessibility of specific brain tissue EVs from living patients. Interesting lines of research have examined both the induction of AD using pathogenic EVs and the sequestration of toxic plaques using exogenous healthy EVs.

It difficult to distinguish among EV types simply on the basis of protein markers or size alone. To better interpret and replicate the experimental results of exosome studies, combined exosome isolation methods as well as improved techniques for accurate purification and characterization are recommended. In addition, a crowdsourcing knowledgebase currently allows researchers in the EV field to track the latest EV biology and methodology ([@B104]).

In recent years, research has been focused on BDEs to attempt to solve questions of brain-associated disorders using blood biopsies. Exosomes isolated from plasma were used to enrich BDEs ([@B162]; [@B143]). This study demonstrated that both the number of neural-derived exosomes as well as the expression of Aβ, neurofilament light chain, and high-mobility group box 1 potentially act as biomarkers of neuropsychological impairment in HIV ([@B162]). BDEs from plasma have also been tested in a pilot study to examine protein biomarkers for patients with major depressive disorder ([@B98]). Moreover, in military personal with mild traumatic brain injuries, compared with controls, the levels of tau, Aβ42, and IL-10 deposited by BDEs were elevated ([@B98]). Cargo proteins and miRNA from astrocytic-derived exosomes have been analyzed to obtain mechanistic insight into AD ([@B63]). Additionally, other cell-derived exosomes have also been researched for other brain-related disorders. The ability to access BDEs in plasma and other biological body fluids such as CSF and urine shows potential for clinical use in treating nervous system disorders.

Conclusion {#S8}
==========

Although the domain of exosome investigation, especially BDEs, remains relatively novel, attractive evidence from other fields demonstrates that investigation of exosomes can afford insight into the disease mechanisms and processes associated with AD and treatment responses. Currently, increased research on exosomes has focused on biomarkers of the course of AD and their ability to mediate cell-to-cell communication in the nervous system. However, additional work is needed with respect to the mechanisms of bi-directional transport of cargo-carrying exosomes across the BBB, the alterations in the number or size of exosomes secreted, changes in cargo constituents, and identification of differences in specific cell types. Meantime, it is necessary to take into consideration that several preparations may contain another type of EVs given the procedure used to obtain them. Exosomes derived from cells in the CNS have tremendous biomarker potential because they may reverse physiological changes in nervous system disorders, and these changes can be tested in the periphery.
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α -SYN

:   α -synuclein

A β

:   amyloid β -protein

AD

:   Alzheimer's disease

ALIX

:   ALG-2-interacting protein X

AMPA

:   α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

Apo-E

:   apolipoprotein E

APP

:   amyloid precursor protein

ARF6

:   ADP ribosylation factor 6

BACE1

:   beta-secretase 1

BBB

:   blood brain barrier

BDNF

:   brain derived neurotrophic factor

BDEs

:   brain derived exosomes

BIN1

:   Bridging I Ntegrator 1

cAMP

:   cyclic adenosine monophosphate

CD

:   Cluster of differentiation

CNS

:   central nervous system

CREB1

:   cAMP responsive element binding protein 1

CSF

:   cerebrospinal fluid

CT

:   computed tomography

ESCRT

:   the endosomal sorting complex required for transport

ECG

:   Electrocardiography

EE

:   early endosome

EGFR

:   epidermal growth factor receptor

EVs

:   extracellular vesicles

gDNA

:   genomic DNA

GAP43

:   growth associated protein 43

HSP

:   heat shock protein

IRS1

:   insulin receptor substrate 1

Iba1

:   ionized calcium-binding adapter molecule 1

IGF1

:   insulin-like growth factor 1

IL-1 β

:   interleukin 1 beta

ILVs

:   intraluminal vesicles

LE

:   late endosome

L1CAM

:   neuronal L1 cell adhesion molecule

LRP6

:   LDL receptor related protein

MCI

:   mild cognitive impairment

miRNA

:   micro ribonucleic acid

MMPs

:   matrix metalloproteinase regulators

MRI

:   magnetic resonance imaging

mRNA

:   messenger ribonucleic acid

MS

:   multiple sclerosis

MSCs

:   mesenchymal stromal cells

MVBs

:   multivesicular bodies

MVEs

:   multivesicular endosomes

Neuro-2a

:   Murine neuroblastoma

nSMase2

:   neutral sphingomyelinase-2

NSCs

:   neural stem cells

NTA

:   nanoparticle tracking analysis

PD

:   Parkinson's disease

PrP

:   prion protein

p-S 396-tau

:   Tau phosphorylation at serine 396

p-T 181-tau

:   Tau phosphorylation at threonine 181

qPCR real-time

:   quantitative polymerase chain reaction

REST

:   re1 silencing transcription factor

S1P

:   sphingosine-1-phosphate

S1PR

:   S1P receptor

siRNA

:   small interfering ribonucleic acid

SMS2

:   sphingomyelin synthase 2

sMVBs

:   secretory multivesicular bodies

TGF β

:   transforming growth factor beta

TSG101

:   tumor susceptibility gene 101 protein.
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